Boston Scientific Corp. (BSX) announced that the CHAMPION-AF global clinical trial successfully met all primary and secondary safety and efficacy endpoints. The study compared the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device with non-vitamin K antagonist oral anticoagulants (NOACs) as a first-line therapy for stroke risk reduction in patients with non-valvular atrial fibrillation (NVAF).
Key findings revealed that the WATCHMAN FLX device provided statistically superior protection from bleeding while demonstrating similar efficacy to blood thinners in reducing stroke risk among NVAF patients.
The results were presented as a late-breaking clinical trial at the American College of Cardiology's Annual Scientific Session & Expo and were simultaneously published in The New England Journal of Medicine, underscoring the potential of WATCHMAN FLX as a safe and effective alternative to long-term anticoagulant therapy. BSX closed Friday's regular trading at $69.17 down $1.00 or 1.43%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.